Possibilities of palliative chemotherapy in patients with locally advanced and metastatic pancreatic cancer
Open Access
- 22 December 2020
- journal article
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 7 (4), 118-134
- https://doi.org/10.17709/2409-2231-2020-7-4-10
Abstract
Currently, pancreatic cancer remains one of the most unfavorable tumor pathologies, characterized by pronounced difficulties in diagnostics and treatment, a significant impact on the ability to work and quality of life of patients, and low indicators of patient life expectancy. Features of the development of malignant neoplasms of this localization contribute to limiting the possibility of performing radical surgery, and therefore a special role in the treatment of patients with pancreatic cancer is assigned to chemotherapy. Specific systemic drug therapy for this pathology is the most important and, in the majority of cases, mandatory element of treatment. It can be carried out in a neoadjuvant, adjuvant and independent mode, include mono- or multi- component schemes, and be combined with other types of systemic or local antitumor effects. The choice of chemotherapy regimen depends primarily on the General somatic status of the patient and is determined by the potential toxicity of a particular combination of cytostatics. This review of the literature demonstrates the effectiveness of various chemotherapy regimens in patients with stage III–IV pancreatic cancer in the first and second lines, describes the frequency of adverse reactions to treatment and their nature, and mentions ways to reduce the toxicity of multicomponent drug therapy regimens. This review is based on the analysis of scientific sources of the Internet resource "National Center for Biotechnological Information".Keywords
This publication has 50 references indexed in Scilit:
- Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular QuestionsInternational Journal of Molecular Sciences, 2019
- Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approachesRadiation Oncology, 2019
- Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomesWorld Journal of Gastroenterology, 2018
- Inherited pancreatic cancerChinese Clinical Oncology, 2017
- Pancreatic Ductal Adenocarcinoma: Current and Evolving TherapiesInternational Journal of Molecular Sciences, 2017
- Recent progress in pancreatic cancerCA: A Cancer Journal for Clinicians, 2013
- Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST StudyJournal of Clinical Oncology, 2013
- Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic CancerJournal of Clinical Oncology, 2009
- Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology GroupJournal of Clinical Oncology, 2007
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997